Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries

Authors: Jacob Creswell, Andrew J Codlin, Emmanuel Andre, Mark A Micek, Ahmed Bedru, E Jane Carter, Rajendra-Prasad Yadav, Andrei Mosneaga, Bishwa Rai, Sayera Banu, Miranda Brouwer, Lucie Blok, Suvanand Sahu, Lucica Ditiu

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

The Xpert MTB/RIF assay has garnered significant interest as a sensitive and rapid diagnostic tool to improve detection of sensitive and drug resistant tuberculosis. However, most existing literature has described the performance of MTB/RIF testing only in study conditions; little information is available on its use in routine case finding. TB REACH is a multi-country initiative focusing on innovative ways to improve case notification.

Methods

We selected a convenience sample of nine TB REACH projects for inclusion to cover a range of implementers, regions and approaches. Standard quarterly reports and machine data from the first 12 months of MTB/RIF implementation in each project were utilized to analyze patient yields, rifampicin resistance, and failed tests. Data was collected from September 2011 to March 2013. A questionnaire was implemented and semi-structured interviews with project staff were conducted to gather information on user experiences and challenges.

Results

All projects used MTB/RIF testing for people with suspected TB, as opposed to testing for drug resistance among already diagnosed patients. The projects placed 65 machines (196 modules) in a variety of facilities and employed numerous case-finding strategies and testing algorithms. The projects consumed 47,973 MTB/RIF tests. Of valid tests, 7,195 (16.8%) were positive for MTB. A total of 982 rifampicin resistant results were found (13.6% of positive tests). Of all tests conducted, 10.6% failed. The need for continuous power supply was noted by all projects and most used locally procured solutions. There was considerable heterogeneity in how results were reported and recorded, reflecting the lack of standardized guidance in some countries.

Conclusions

The findings of this study begin to fill the gaps among guidelines, research findings, and real-world implementation of MTB/RIF testing. Testing with Xpert MTB/RIF detected a large number of people with TB that routine services failed to detect. The study demonstrates the versatility and impact of the technology, but also outlines various surmountable barriers to implementation. The study is not representative of all early implementer experiences with MTB/RIF testing but rather provides an overview of the shared issues as well as the many different approaches to programmatic MTB/RIF implementation.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization: Global Tuberculosis Report 2013. 2012, Geneva, Switzerland: World Health Organization World Health Organization: Global Tuberculosis Report 2013. 2012, Geneva, Switzerland: World Health Organization
2.
go back to reference World Health Organization: Policy Statement: Automated real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. 2011, Geneva, Switzerland: World Health Organization World Health Organization: Policy Statement: Automated real-time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. 2011, Geneva, Switzerland: World Health Organization
3.
go back to reference World Health Organization: Rapid Implementation of the Xpert MTB/RIF diagnostic test. 2011, Geneva, Switzerland: World Health Organization World Health Organization: Rapid Implementation of the Xpert MTB/RIF diagnostic test. 2011, Geneva, Switzerland: World Health Organization
4.
go back to reference Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010, 363 (11): 1005-1015.CrossRefPubMedPubMedCentral Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O’Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD: Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010, 363 (11): 1005-1015.CrossRefPubMedPubMedCentral
5.
go back to reference Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N: Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013, 1: CD009593-PubMed Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N: Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013, 1: CD009593-PubMed
7.
go back to reference Bates M, O’Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A: Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis. 2012, 13 (1): 36-42.CrossRefPubMed Bates M, O’Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A: Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis. 2012, 13 (1): 36-42.CrossRefPubMed
8.
go back to reference Lawn SD, Kerkhoff AD, Vogt M, Wood R: High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr. 2012, 60 (3): 289-294.CrossRefPubMedPubMedCentral Lawn SD, Kerkhoff AD, Vogt M, Wood R: High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay. J Acquir Immune Defic Syndr. 2012, 60 (3): 289-294.CrossRefPubMedPubMedCentral
9.
go back to reference Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP: Rapid diagnosis of pediatric intrathoracictuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J. 2012, 31 (12): 1316-CrossRefPubMed Walters E, Gie RP, Hesseling AC, Friedrich SO, Diacon AH, Gie RP: Rapid diagnosis of pediatric intrathoracictuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J. 2012, 31 (12): 1316-CrossRefPubMed
10.
go back to reference Friedrich SO, von Groote-Bidlingmaier F, Diacon AH: Xpert MTB/RIF assay for the diagnosis of pleural tuberculosis. J Clin Microbiol. 2011, 49 (12): 4341-4342.CrossRefPubMedPubMedCentral Friedrich SO, von Groote-Bidlingmaier F, Diacon AH: Xpert MTB/RIF assay for the diagnosis of pleural tuberculosis. J Clin Microbiol. 2011, 49 (12): 4341-4342.CrossRefPubMedPubMedCentral
11.
go back to reference Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC, Zemanay W, Nicol MP: Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012, 55 (8): 1088-1095.CrossRefPubMedPubMedCentral Zar HJ, Workman L, Isaacs W, Munro J, Black F, Eley B, Allen V, Boehme CC, Zemanay W, Nicol MP: Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012, 55 (8): 1088-1095.CrossRefPubMedPubMedCentral
12.
go back to reference Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM: Diagnostic performance of Genotype® MTBDRplus Version 2 line probe assay is equivalent to the Xpert® MTB/RIF assay. J Clin Microbiol. 2012, 50 (11): 3712-3716.CrossRefPubMedPubMedCentral Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM: Diagnostic performance of Genotype® MTBDRplus Version 2 line probe assay is equivalent to the Xpert® MTB/RIF assay. J Clin Microbiol. 2012, 50 (11): 3712-3716.CrossRefPubMedPubMedCentral
13.
go back to reference Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA: An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2012, 74 (2): 207-209.CrossRefPubMed Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA: An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2012, 74 (2): 207-209.CrossRefPubMed
14.
go back to reference Dheda K, Ruhwald M, Theron G, Peter J, Yam WC: Point-of-care diagnosis of tuberculosis: past, present and future. Respirology. 2012, 18 (2): 217-232.CrossRef Dheda K, Ruhwald M, Theron G, Peter J, Yam WC: Point-of-care diagnosis of tuberculosis: past, present and future. Respirology. 2012, 18 (2): 217-232.CrossRef
15.
go back to reference Peters D, Grant T, Jonny P, Keertan D: Should Xpert® MTB/RIF be rolled out in low-income countries? [correspondence]. Int J Tuberc Lung Dis. 2012, 16 (5): 702-703.CrossRefPubMed Peters D, Grant T, Jonny P, Keertan D: Should Xpert® MTB/RIF be rolled out in low-income countries? [correspondence]. Int J Tuberc Lung Dis. 2012, 16 (5): 702-703.CrossRefPubMed
16.
go back to reference Trébucq A, Harries AD, Rieder HL: In reply to ‘Should Xpert® MTB/RIF be rolled out in low-income countries?’. Int J Tuberc Lung Dis. 2012, 16 (5): 703-704.CrossRef Trébucq A, Harries AD, Rieder HL: In reply to ‘Should Xpert® MTB/RIF be rolled out in low-income countries?’. Int J Tuberc Lung Dis. 2012, 16 (5): 703-704.CrossRef
17.
go back to reference Singh JA, Bhan A: The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert® MTB/RIF. Int J Tuberc Lung Dis. 2011, 15 (12): 1563-CrossRefPubMed Singh JA, Bhan A: The ethics of national tuberculosis programmes in low-income countries not rolling out Xpert® MTB/RIF. Int J Tuberc Lung Dis. 2011, 15 (12): 1563-CrossRefPubMed
18.
go back to reference Dowdy DW, Cattamanchi A, Steingart KR, Pai M: Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med. 2011, 8 (7): e1001063-CrossRefPubMedPubMedCentral Dowdy DW, Cattamanchi A, Steingart KR, Pai M: Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med. 2011, 8 (7): e1001063-CrossRefPubMedPubMedCentral
19.
go back to reference Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F: Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011, 8 (11): e1001120-CrossRefPubMedPubMedCentral Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F: Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011, 8 (11): e1001120-CrossRefPubMedPubMedCentral
21.
go back to reference Small P, Pai M: Tuberculosis diagnosis - time for a game change. N Engl J Med. 2010, 363: 1070-1071.CrossRefPubMed Small P, Pai M: Tuberculosis diagnosis - time for a game change. N Engl J Med. 2010, 363: 1070-1071.CrossRefPubMed
22.
go back to reference Denkinger CM, Grenier J, Minion J, Pai M: Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol. 2012, 50 (7): 2455-2461.CrossRefPubMedPubMedCentral Denkinger CM, Grenier J, Minion J, Pai M: Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics. J Clin Microbiol. 2012, 50 (7): 2455-2461.CrossRefPubMedPubMedCentral
26.
go back to reference Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL: Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis. 2011, 15: 1567-1572.CrossRefPubMed Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL: Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?. Int J Tuberc Lung Dis. 2011, 15: 1567-1572.CrossRefPubMed
27.
go back to reference Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A: Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013, 13: 349-361.CrossRefPubMedPubMedCentral Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A: Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis. 2013, 13: 349-361.CrossRefPubMedPubMedCentral
29.
go back to reference World Health Organization: Systematic screening for active tuberculosis – principles and recommendations. 2013, Geneva, Switzerland: World Health Organization World Health Organization: Systematic screening for active tuberculosis – principles and recommendations. 2013, Geneva, Switzerland: World Health Organization
30.
go back to reference Codlin AJ, Javaid M, Qazi F, Khan MS: Novel methodology to assess sputum smear microscopy quality in private laboratories. BMC Infect Dis. 2012, 12: 331-CrossRefPubMedPubMedCentral Codlin AJ, Javaid M, Qazi F, Khan MS: Novel methodology to assess sputum smear microscopy quality in private laboratories. BMC Infect Dis. 2012, 12: 331-CrossRefPubMedPubMedCentral
32.
go back to reference GeneXpertDx System: Operator Manual Software version 4.0. e-dok.rm.dk/e-dok/e_702615.nsf/$CXIV/ATTACH-RMAP-8QVAXS/$FILE/Operator%20Manual%20Rev%20C[1].1%204.0%20Version%20GX%20Dx%20Operator%20Manual_EN%20Mar11.pdf GeneXpertDx System: Operator Manual Software version 4.0. e-dok.rm.dk/e-dok/e_702615.nsf/$CXIV/ATTACH-RMAP-8QVAXS/$FILE/Operator%20Manual%20Rev%20C[1].1%204.0%20Version%20GX%20Dx%20Operator%20Manual_EN%20Mar11.pdf
35.
go back to reference World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and response. 2010, Geneva, Switzerland: World Health Organization World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and response. 2010, Geneva, Switzerland: World Health Organization
36.
go back to reference Pai NP, Vadnais C, Denkinger C, Engel N, Pai M: Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012, 9 (9): e1001306-CrossRefPubMedPubMedCentral Pai NP, Vadnais C, Denkinger C, Engel N, Pai M: Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012, 9 (9): e1001306-CrossRefPubMedPubMedCentral
37.
go back to reference Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, for the TB-NEAT team: Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013, doi:10.1016/S0140-6736(13)62073-5. [Epub ahead of print] Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, for the TB-NEAT team: Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013, doi:10.1016/S0140-6736(13)62073-5. [Epub ahead of print]
38.
go back to reference Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M: Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?. Eur Respir J. 2013, 42 (2): 544-547. doi:10.1183/09031936.00081113CrossRefPubMed Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M: Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics?. Eur Respir J. 2013, 42 (2): 544-547. doi:10.1183/09031936.00081113CrossRefPubMed
40.
go back to reference World Health Organization: Definitions and Reporting Framework for Tuberculosis – 2013 revision. 2013, Geneva, Switzerland: World Health Organization World Health Organization: Definitions and Reporting Framework for Tuberculosis – 2013 revision. 2013, Geneva, Switzerland: World Health Organization
Metadata
Title
Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries
Authors
Jacob Creswell
Andrew J Codlin
Emmanuel Andre
Mark A Micek
Ahmed Bedru
E Jane Carter
Rajendra-Prasad Yadav
Andrei Mosneaga
Bishwa Rai
Sayera Banu
Miranda Brouwer
Lucie Blok
Suvanand Sahu
Lucica Ditiu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-2

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.